Import from '@womanrx/ui'

Is Egrifta (Tesamorelin) Legal in Texas?

The Short Answer on Texas Legality

Egrifta (tesamorelin) is fully legal in Texas. It is not a controlled substance under the federal Controlled Substances Act, and Texas has not placed it on any state-level restricted or scheduled drug list. A licensed Texas provider can prescribe it, and a licensed Texas pharmacy, or a federally compliant 503A/503B compounding pharmacy, can dispense it. What you cannot legally do is purchase tesamorelin without a prescription or from a source that is not a licensed pharmacy.

The confusion around legality usually comes from two sources: the broader peptide grey market, and the FDA's evolving policies on compounded peptides. Tesamorelin sits in a cleaner legal position than many other peptides because it has an FDA-approved branded product on the market.

Federal Framework: Why FDA Approval Matters

The FDA approved Egrifta in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A reformulated version, Egrifta SV (2 mg/mL), received approval in 2019. Because an FDA-approved finished product exists, compounders face tighter restrictions: under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, a compounded drug cannot be "essentially a copy" of a commercially available product unless there is a documented clinical difference or documented shortage. As of the date of this article, Egrifta SV is not on the FDA drug shortage list, which means compounding pharmacies must proceed carefully and document medical necessity.

Texas State Framework

Texas regulates pharmacy practice through the Texas State Board of Pharmacy (TSBP) and medical prescribing through the Texas Medical Board (TMB). Neither body has issued a specific ban or restriction on tesamorelin beyond the federal framework already in place. Under Texas Occupations Code Chapter 551 and the Texas Pharmacy Act, any drug that is not a controlled substance may be compounded and dispensed when a valid patient-prescriber relationship exists and the prescription reflects a legitimate medical need. Telehealth prescribing of non-controlled substances is permitted in Texas following the expansion of telehealth rules after 2021.

The Compounding Pharmacy Question

If you are seeking tesamorelin at a lower cost through a compounding pharmacy rather than Egrifta SV by brand, the legal pathway depends on:

1. Whether the compounding pharmacy is a licensed 503A pharmacy (patient-specific prescriptions) or a 503B outsourcing facility (larger batch production, stricter FDA oversight).
2. Whether your prescription documents a clinical difference from the branded product, such as a different concentration, delivery device, or combination formulation.
3. Whether the active pharmaceutical ingredient (API) source is from an FDA-registered facility.

Tesamorelin is not on the FDA's list of bulk drug substances that may not be used in compounding. That absence means compounding is not categorically prohibited, but it does not eliminate the "essentially a copy" restriction when the brand-name product is available and not in shortage. Your prescriber and compounding pharmacy share responsibility for navigating this correctly.

What Tesamorelin Actually Does: The Physiology Women Need to Know

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland, stimulating pulsatile release of endogenous growth hormone (GH). GH then triggers insulin-like growth factor-1 (IGF-1) production in the liver, and the net effect on adipose tissue is preferential reduction of visceral fat (the fat surrounding abdominal organs) rather than subcutaneous fat.

Why This Matters Differently for Women

Women's GH secretion is already sexually dimorphic. Premenopausal women secrete GH in higher-amplitude pulses than men of the same age, largely because estrogen amplifies GH release. Research published in the Journal of Clinical Endocrinology and Metabolism confirmed that estrogen modulates GH pulsatility and IGF-1 production in a dose-dependent way. After menopause, estrogen falls, GH pulse amplitude decreases, and visceral fat accumulation accelerates. This is why postmenopausal women often notice a shift from gluteal-femoral fat distribution to central adiposity even without significant weight gain.

In the Phase III LIPO-010 trial, which supported Egrifta's approval, approximately 40% of enrolled participants were women. The primary outcome, reduction in visceral adipose tissue (VAT) measured by CT scan, was significant: a mean reduction of approximately 18% in VAT versus placebo at 26 weeks. Female-specific subgroup analyses were not the primary focus of the trial, which is a real gap in the evidence base. Results in women were directionally consistent with the overall population, but women have been underrepresented in lipodystrophy peptide trials broadly, and that honest caveat belongs here.

GH, IGF-1, and the Menstrual Cycle

In women of reproductive age, GH and IGF-1 fluctuate across the menstrual cycle. IGF-1 peaks in the late follicular phase and is influenced by estradiol levels. Tesamorelin raises IGF-1 measurably. The LIPO-010 trial reported that IGF-1 standard deviation (SD) scores increased by approximately 1.0 SD from baseline. In a premenopausal woman with already-variable IGF-1, monitoring is more important, not less. Your provider should check IGF-1 at baseline and at 3-month intervals.

Who This Is Right For, and Who It Is Not

Conditions Where Tesamorelin May Be Relevant to Women

HIV-associated lipodystrophy (the approved indication). Women living with HIV on antiretroviral therapy are the only group with direct FDA-approved access to Egrifta. Lipodystrophy, characterized by central fat accumulation and peripheral fat wasting, affects women on older nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors. The FDA-approved prescribing information specifies this population exclusively.

Postmenopausal women with central adiposity (off-label). This is the most common off-label context in which women in Texas are asking about tesamorelin. The rationale is physiologically sound: declining GH pulsatility after menopause contributes to visceral fat accumulation, and tesamorelin addresses that mechanism directly. A 2020 review in Obesity Reviews noted that GH secretagogues and GHRH analogues show promising VAT reduction in non-HIV populations, but large randomized controlled trials in postmenopausal women specifically are lacking. Extrapolation from HIV trial data is the current clinical reality.

PCOS with metabolic features. Women with polycystic ovary syndrome (PCOS) often have insulin resistance and excess visceral fat independent of overall BMI. There is no published RCT of tesamorelin in PCOS populations. Any use in this context is off-label with limited direct evidence. A clinician choosing this path should document the rationale and monitor closely.

Who Should Not Use Tesamorelin

• Women who are pregnant or actively trying to conceive (see pregnancy section below)
• Women with active malignancy or a history of GH-sensitive cancers
• Women with diabetic retinopathy (tesamorelin raises IGF-1, which may worsen retinopathy)
• Women with known pituitary tumor or hypothalamic disease affecting pituitary function
• Women with hypersensitivity to tesamorelin or mannitol (an excipient in Egrifta SV)

Women with Type 2 diabetes should use tesamorelin with caution. The prescribing label notes that tesamorelin may cause glucose intolerance and increase the risk of diabetes or worsen glycemic control. In the LIPO-010 trial, fasting glucose increased by a mean of approximately 4.2 mg/dL in the tesamorelin group versus 0.5 mg/dL in placebo.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age.

Pregnancy

Tesamorelin is contraindicated in pregnancy. The FDA label assigns no formal letter category under the old system (the drug was approved after the 2015 Pregnancy and Lactation Labeling Rule transition), but the prescribing information states plainly that Egrifta SV should not be used during pregnancy. Animal reproductive toxicity studies showed embryofetal harm at doses below the human clinical dose. There are no adequate human data.

If you are pregnant, you must stop tesamorelin immediately. If you discover a pregnancy during treatment, contact your provider the same day.

Contraception Requirement

Women of reproductive potential taking tesamorelin should use reliable contraception. Because tesamorelin raises IGF-1 and GH, and because the hormonal milieu of early pregnancy is tightly regulated, any disruption of GH signaling during organogenesis carries a theoretical risk that has not been fully characterized in humans. Your prescriber should discuss contraception choices with you before starting treatment.

Lactation

No human data exist on whether tesamorelin or its metabolites transfer into breast milk. The molecular weight of tesamorelin (about 5,135 daltons) is high, which typically limits transfer into milk, but high molecular weight alone does not guarantee safety. LactMed, the NIH drug and lactation database, does not list tesamorelin specifically, reflecting the absence of published data. Given the lack of evidence, the conservative clinical position is to avoid tesamorelin during breastfeeding.

Perimenopause and Menopause: Adjusted Considerations

In perimenopausal women, fluctuating estrogen levels make IGF-1 monitoring less predictable. Your provider may want to check IGF-1 more frequently, at 6-week rather than 12-week intervals, during the transition phase. Postmenopausal women on hormone therapy (HT) should know that estrogen increases GH secretion and IGF-1, so the additive effect with tesamorelin may push IGF-1 above the normal range. This is not an absolute contraindication, but it requires baseline and follow-up IGF-1 monitoring with dose adjustment if IGF-1 SD score exceeds +2.

How to Get Egrifta (Tesamorelin) in Texas

Step 1: Establish Care with a Licensed Texas Provider

You need a prescription from a provider licensed by the Texas Medical Board. This can be a physician (MD or DO), a nurse practitioner, or a physician assistant operating within their scope of practice. Telehealth visits with Texas-licensed providers satisfy the patient-prescriber relationship requirement for non-controlled substances under Texas Health and Safety Code Chapter 111.

At your visit, expect the provider to review:

• Your lipid panel and fasting glucose
• Baseline IGF-1 level
• Body composition or waist circumference measurements
• Your HIV status and antiretroviral history if the approved indication applies
• Reproductive status and contraception plan if you are of reproductive age

Step 2: Understand Your Pharmacy Options

Brand-name Egrifta SV is available through specialty pharmacies. Insurance coverage is primarily limited to the FDA-approved indication (HIV lipodystrophy), so off-label use is typically cash-pay. The list price is high, often exceeding $3,000 per month, though manufacturer patient assistance programs exist through Theratechnologies.

Compounded tesamorelin is available through licensed 503A compounding pharmacies at a significantly lower cost, often in the range of $150 to $400 per month, but the legal constraints described above apply. Your prescriber must document clinical differentiation from the branded product, and the compounding pharmacy must use API from an FDA-registered supplier.

Step 3: Monitoring on Therapy

The following monitoring framework applies specifically to women, accounting for hormonal variability:

| Timepoint | What to Check | Women-Specific Note | |---|---|---| | Baseline | IGF-1, fasting glucose, HbA1c, lipid panel, pregnancy test | Confirm contraception plan | | 6 weeks (perimenopausal) | IGF-1 | More frequent due to estrogen flux | | 3 months | IGF-1, fasting glucose | Dose-adjust if IGF-1 SD > +2 | | 6 months | IGF-1, fasting glucose, waist circumference or CT VAT | Assess response; discontinue if no benefit | | Ongoing (every 6 months) | IGF-1, fasting glucose | Monitor for glucose intolerance |

If IGF-1 rises above the upper limit of normal for age and sex, the dose should be reduced or temporarily stopped. The labeled dose is 2 mg subcutaneously once daily; there is no FDA-approved lower dose, but clinical practice sometimes uses 1 mg daily to manage tolerability or excessive IGF-1 elevation.

Side Effects Women Report Most Often

The LIPO-010 trial safety data showed that injection site reactions were the most common adverse effect, occurring in approximately 25% of tesamorelin-treated participants. Other reported effects include:

• Fluid retention and edema (particularly notable if you are also on estrogen therapy, which causes some sodium retention)
• Arthralgias and myalgias
• Nausea
• Paresthesias (tingling, often in the hands and feet)
• Elevated fasting glucose or progression to diabetes

Women on oral estrogen (which undergoes first-pass hepatic metabolism and reduces IGF-1 compared to transdermal estrogen) may see a blunted tesamorelin response because hepatic IGF-1 production is suppressed by oral estrogen. If you are on oral HT and not seeing the expected IGF-1 rise at 3 months, discuss switching to transdermal estrogen with your provider. A study in the Journal of Clinical Endocrinology and Metabolism confirmed that oral but not transdermal estradiol suppresses IGF-1, a pharmacokinetic difference that directly affects tesamorelin response.

The Evidence Gap: What We Do and Do Not Know in Women

Women have been systematically underrepresented in GH-axis peptide trials. The key tesamorelin trials enrolled predominantly men with HIV, reflecting the epidemic demographics of that era. This is not a reason to dismiss tesamorelin for women, but it is a reason to set expectations carefully.

What is directly studied in women: HIV-associated lipodystrophy in women on antiretrovirals, based on female subgroup data from the LIPO-010 and LIPO-011 trials.

What is extrapolated, not directly proven: Off-label use in postmenopausal adiposity, PCOS-related visceral fat, and non-HIV metabolic disease in women. The mechanistic rationale is sound. The RCT evidence in these populations is absent.

The Menopause Society has not issued a position statement on tesamorelin or GHRH analogues specifically. Any provider citing menopause-related indications is working from mechanism and extrapolation. That is not inherently wrong in clinical medicine, but you deserve to know it.

Tesamorelin vs. Other Peptides: Where It Fits for Women

Several other peptides circulate in the wellness and anti-aging space that also target the GH axis, including sermorelin, ipamorelin, and CJC-1295. The legal situation for these differs materially:

• Sermorelin was a previously FDA-approved drug whose approval was withdrawn. Its compounding status is more complex and its legal footprint in Texas is murkier than tesamorelin's.
• Ipamorelin and CJC-1295 are not FDA-approved drugs and exist in a genuine regulatory grey zone. Neither appears on the FDA approved drug list, and neither has an established 503A/503B compounding pathway as of 2025.
• Tesamorelin (Egrifta) has the clearest legal standing of the three because an approved branded product exists and the compound is not on the FDA bulks prohibition list.

If you are comparing options, tesamorelin offers the most defined regulatory pathway for women in Texas, though at a cost premium and with the compounding caveats already noted.

Talking to Your Texas Provider About Tesamorelin

Bring the following to your appointment:

1. Your recent labs (fasting glucose, HbA1c, lipid panel) if available
2. A description of your primary concern (visceral fat, body composition, HIV lipodystrophy)
3. Your current medication list, specifically any hormones, insulin sensitizers, or corticosteroids
4. Your reproductive status and contraception method if applicable
5. Questions about whether your provider will prescribe brand Egrifta SV or work with a 503A compounding pharmacy

A provider who cannot explain the difference between the FDA-approved indication and off-label use, or who dismisses IGF-1 monitoring as unnecessary, is not the right fit for this prescription. AACE clinical guidance on GH axis disorders recommends IGF-1 monitoring for all patients receiving GH-stimulating therapies, and this applies equally to tesamorelin.

The FDA prescribing information for Egrifta SV states that treatment should be discontinued if there is no reduction in VAT after 26 weeks of therapy. This is a concrete clinical endpoint you and your provider should agree on before starting.